HUTCHMED stock rises on a Citi target price increase
Published on 09/04/2026 at 19:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
HUTCHMED (China) Limited stock (US44842L1035) rose after Citi lifted its target price to HK$39 from HK$36 and kept a Buy/High Risk view, while the shares traded at HK$21.36 with volume of 11.6735 million shares and turnover of HK$250 million on September 3, 2026.
Deal math changes the outlook
According to the Citi update reported by Futu News, the bank raised its 2026 to 2028 oncology and immunology revenue forecasts for Hutchmed by 27 percent, 26 percent and 14 percent, and increased EPS estimates to USD 0.08, USD 0.09 and USD 0.13. The same report ties the revision to the GSK licensing deal on HMPL-A830 and says the transaction came earlier than Citi expected.
License value and cash
For investors, the key number is the deal size: the GSK agreement was described as worth up to USD 1.295 billion, including a USD 110 million upfront payment and up to USD 1.185 billion in milestones. A separate report on September 4, 2026 said Hutchmed also expects 2026 oncology and immunology revenue of USD 330 million to USD 450 million.
Another report on September 4, 2026 put first-half 2026 total revenue at USD 278 million, net income attributable to shareholders at USD 16.242 million, and basic EPS at USD 0.02. It also said cash and short-term investments totaled USD 1.375 billion at June 30, 2026, while research and development spending reached USD 78.8 million in the half year.
Hutchmed deal and capital allocation
The latest licensing deal puts Hutchmed's pipeline value, 2026 revenue range and cash position in one frame.
HMPL-A830 in focus
HMPL-A830 is the compound behind the GSK agreement and the reason the market is revaluing the pipeline today. The deal gives GSK worldwide rights outside Greater China, while Hutchmed keeps responsibility for global phase I work that is expected to start in the second half of 2026.
Stock near the Hong Kong close
HUTCHMED stock was quoted at HK$21.36 on September 3, 2026, after a move of 11.6 percent, with volume of 11.6735 million shares and turnover of HK$250 million. The company is traded on HKEX under 13 and Nasdaq under HCM.
HUTCHMED stock facts
- Company: HUTCHMED (China) Limited
- ISIN: US44842L1035
- Ticker: HCM
- Trading venue: Nasdaq, AIM and HKEX
- Price (as of September 3, 2026): HKD 21.36
- Market capitalization: HKD 19,676.15 million
- Sector / Industry: Health Care / Biotechnology
- Index membership: HKEX listed stock
